Eton Pharmaceuticals (ETON) Liabilities and Shareholders Equity (2017 - 2026)

Eton Pharmaceuticals has disclosed Liabilities and Shareholders Equity across 10 years of filings, most recently posting $115.8 million for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity rose 13.9% year-over-year to $115.8 million; the TTM figure through Jun 2026 stood at $414.1 million (up 39.12% YoY), while the FY2025 annual figure was $92.1 million, up 21.01% from the prior year.
• Liabilities and Shareholders Equity came in at $115.8 million for Q2 2026 at Eton Pharmaceuticals, up from $92.1 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $115.8 million in Q2 2026 to a low of $21.5 million in Q3 2022.
• Average Liabilities and Shareholders Equity over 5 years is $52.0 million, with a median of $31.7 million recorded in 2023.
• Year-over-year, Liabilities and Shareholders Equity retreated 25.62% in 2022 and surged 219.5% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $25.0 million in 2022, then increased by 26.81% to $31.7 million in 2023, then surged by 139.83% to $76.1 million in 2024, then increased by 21.01% to $92.1 million in 2025, then increased by 25.72% to $115.8 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $115.8 million in Q2 2026, $92.1 million in Q4 2025, and $104.5 million in Q3 2025.